4967 — Kobayashi Pharmaceutical Co Balance Sheet
0.000.00%
- ¥405bn
- ¥340bn
- ¥166bn
- 83
- 33
- 66
- 68
Annual balance sheet for Kobayashi Pharmaceutical Co, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 94,338 | 109,046 | 104,533 | 79,836 | 65,745 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 52,829 | 55,147 | 47,853 | 52,984 | 49,384 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 164,225 | 181,889 | 172,892 | 158,331 | 144,468 |
Net Property, Plant And Equipment | 20,821 | 22,524 | 34,778 | 47,665 | 67,448 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 238,366 | 252,554 | 255,827 | 267,473 | 265,368 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 50,107 | 50,703 | 51,809 | 56,111 | 46,423 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 55,783 | 56,954 | 57,927 | 62,657 | 51,901 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 182,583 | 195,600 | 197,900 | 204,816 | 213,467 |
Total Liabilities & Shareholders' Equity | 238,366 | 252,554 | 255,827 | 267,473 | 265,368 |
Total Common Shares Outstanding |